Amiodarone has an important place in the treatment of severe cardiac rhythm disorders where other treatments either cannot be used or have failed; however, its use requires regular monitoring due to potential toxicities. Primary and secondary care clinicians have recognised that it would be beneficial to review all patients taking amiodarone in Wales to establish the need for ongoing treatment. The enclosed documentation has been developed to assist this process.
|
This resource has been retired and is no longer considered an AWMSG-endorsed resource. The resource underwent an assessment for review in February 2025. At that time, members of the All Wales Prescribing Advisory Group (AWPAG) considered it appropriate to retire the resource. The content contained within the resource was considered to be out of date and other suitable alternative guidance was available (e.g. Guidelines for the management of atrial fibrillation (ESC 2024) and NG196 Atrial fibrillation (NICE)), AWPAG members considered it most appropriate for the resource to be retired at this time. If you think this resource should be reconsidered for review, please get in touch with AWTTC by emailing awttc@nhs.wales.uk. |
⇩ Prescribing of Amiodarone for Atrial Fibrillation and Atrial Flutter in Wales 2MB (PDF) |
(September 2016, Retired June 2025)